Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 10Unknown 5Recruiting 5Not yet recruiting 4Active not recruiting 4Withdrawn 2Terminated 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 5

Conditions

Carcinoma, Non-Small-Cell Lung 40Pancreatic Neoplasms 17Breast Neoplasms 17Esophageal Neoplasms 14Neoplasms 13Stomach Neoplasms 12Lung Neoplasms 12Triple Negative Breast Neoplasms 11Rectal Neoplasms 11Neoplasm Metastasis 11Esophageal Squamous Cell Carcinoma 11Uterine Cervical Neoplasms 10Colorectal Neoplasms 10Small Cell Lung Carcinoma 9Ovarian Neoplasms 9Head and Neck Neoplasms 7Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Nasopharyngeal Carcinoma 5Leukemia, Myeloid, Acute 5Endometrial Neoplasms 5Recurrence 4NSCLC 4Mouth Neoplasms 4Colonic Neoplasms 4Lymphoma 3Glioma 3Cholangiocarcinoma 3Adenocarcinoma Of Esophagus 3Urinary Bladder Neoplasms 2

Interventions

pembrolizumab 61Cisplatin 37Carboplatin 23Radiotherapy 21Cetuximab 19Magnetic Resonance Spectroscopy 18Paclitaxel 17Specimen Handling 13Docetaxel 12Fluorouracil 11Nivolumab 10tislelizumab 9Surgical Procedures, Operative 8Radiotherapy, Intensity-Modulated 7Radiation 7cemiplimab 6Standard of Care 6Platinum 6Chemoradiotherapy 6Biopsy 61,2-diaminocyclohexaneplatinum II citrate 6toripalimab 5Drug Therapy 5130-nm albumin-bound paclitaxel 5atezolizumab 4Taxes 4Ipilimumab 4Immunotherapy 4Fluorodeoxyglucose F18 4Cyclophosphamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Squamous Cell Carcinoma of Head and Neck × Drug Therapy × Clear all
NCT07447570 2026-03-03

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
27 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06943820 2025-06-03

AK129 Combination Therapy for Advanced Solid Tumors

Akeso

Phase 1/2 Recruiting
230 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04857164 2025-01-28

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
150 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04747054 2024-10-26

PembroMetaRT

UNICANCER

Phase 3 Recruiting
102 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Neoplasm Metastasis

NCT04220749 2020-09-04

Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Recruiting
68 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡